MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.
about
The case for inhibiting p38 mitogen-activated protein kinase in heart failureA-kinase anchoring protein Lbc coordinates a p38 activating signaling complex controlling compensatory cardiac hypertrophyp38 MAP kinases in the heartNFAT and CREB regulate Kaposi's sarcoma-associated herpesvirus-induced cyclooxygenase 2 (COX-2)The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure.Common therapeutic targets in cardiometabolic diseasePhosphoprotein abundance changes in hypertensive cardiac remodeling.Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling.Maternal diet-induced obesity programs cardiovascular dysfunction in adult male mouse offspring independent of current body weightReversibility of adverse, calcineurin-dependent cardiac remodeling.Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivoAMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism.Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin SensitivityCaveolar remodeling is a critical mechanotransduction mechanism of the stretch-induced L-type Ca2+ channel activation in vascular myocytes.Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.Electrical and mechanical stimulation of cardiac cells and tissue constructs.Disruption of Nox2 and TNFRp55/p75 eliminates cardioprotection induced by anisomycin.Characterization of hsp27 kinases activated by elevated aortic pressure in heart.Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical TrialsC-C Motif Chemokine Receptor 9 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and DysfunctionMitogen-activated protein kinase-activated protein kinases 2 and 3 regulate SERCA2a expression and fiber type composition to modulate skeletal muscle and cardiomyocyte function.Cyclic AMP increases COX-2 expression via mitogen-activated kinase in human myometrial cells.Gene expression profiles in engineered cardiac tissues respond to mechanical loading and inhibition of tyrosine kinases.The Protective Effects of Ivabradine in Preventing Progression from Viral Myocarditis to Dilated Cardiomyopathy.The many faces of p38 mitogen-activated protein kinase in progenitor/stem cell differentiation.Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014).Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt.Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress.The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling.Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy.SDF-1 induces TNF-mediated apoptosis in cardiac myocytes.MK5 haplodeficiency attenuates hypertrophy and preserves diastolic function during remodeling induced by chronic pressure overload in the mouse heart.Circulating microRNA signature for the diagnosis of childhood dilated cardiomyopathy.A Disintegrin and Metalloprotease-22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway.A-Kinase Anchoring Protein-Lbc: A Molecular Scaffold Involved in Cardiac Protection.Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling.Cyclovirobuxinum D alleviates cardiac hypertrophy in hyperthyroid rats by preventing apoptosis of cardiac cells and inhibiting the p38 mitogen-activated protein kinase signaling pathway.Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome.The serine/threonine-protein kinase/endoribonuclease IRE1α protects the heart against pressure overload-induced heart failure.Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes.
P2860
Q28080674-BCE8DE16-D935-4E61-8DA7-CF728435893EQ28570967-18C38913-68CD-4B10-B766-44678B048301Q28603117-BE0C3C17-D773-4199-9F75-5A2A02BDCC4FQ33718186-F793250F-A156-41C1-A9DD-96ABB5F1A1EFQ34148893-81629D3E-6D42-4E9D-AAEC-DBEB700D362DQ34251343-24FB7022-273D-461C-BBB5-031BAAE28E91Q34289975-487FC649-6175-4C5A-8417-20C277479D9CQ34387308-57FBBF07-60F7-4724-BDB4-F6C00D2B5F0DQ34628879-69801438-17DE-4804-9FA9-85DB7EAA0D4CQ35189672-890FEE5C-D57E-4C53-8EC5-1922AE79AA9AQ35713452-D564CF27-8FB3-4D63-ACE7-A5300A16CEF1Q36048973-46D92F40-AF91-4003-A0AA-C9054D2FAF12Q36104668-B238B11F-84B4-419F-B73D-5A78C3AAD151Q36311623-E1EA55F9-016C-43FB-A40D-6542AA49C3D2Q36402509-F1A6AA79-B203-4189-8F50-6B323C3B444BQ36421781-8FE5170D-FE04-4F90-9FB7-53EA3372CE4CQ36454212-CA17DA3E-CF77-4D0C-8E00-E7D391F84D8FQ36544841-1065F2AE-EF14-4740-B3EA-76FC55390481Q36849634-EC4E8D9D-D288-475C-B7C8-7EC00E736B5DQ36956778-9AA90121-FE7C-4448-A78A-6D5751CC6DC3Q36978298-1ABE4DAC-BE9E-4F96-9A7D-40A96D88C40DQ37295519-4ED42C9D-731B-40B6-A148-17FBF3E7FEE7Q37344100-768EE2DD-B43C-464B-9E63-C49992562D85Q37383105-22AA3391-8E31-448E-8DC9-DD3914666027Q38019033-807492C4-C9CA-447B-866C-A06EBAE04CE0Q38546917-683D9EC7-18CF-4004-9638-FE524C423E60Q38739980-77177B55-4984-4E2D-BD1A-F068B3933612Q41783370-A1DA1A2D-999D-4414-80A4-E46272F3DEBEQ44729962-9E120487-725D-40C1-8440-607F37D0203EQ46038393-A02E72E5-0178-496B-B282-E86169E08641Q47298475-953A9EFF-0185-4B60-A77C-A35FFF785DC8Q48247128-D6BF048D-E54A-4987-93C7-3373E09AF4A6Q49438663-21E08DDA-F79A-47BD-9155-9F1B6454E162Q49875840-4FC90F70-5D90-4E85-91B9-BD257CBFE167Q50117582-33C03A7B-2FB3-436B-ABEE-E6DB11AA12D9Q50866622-13B180C8-13FC-4D22-8B37-59B4FCC9208CQ52876737-7B3AA319-8B5E-484B-9B8B-31247CA5049AQ54610891-327CEF81-7291-4A25-906B-0593C1E39347Q54978911-2D2856E0-B1FD-4CD2-9B54-CD6C2F3E71BFQ54981841-A07D577A-B78D-427A-AA41-79138F573099
P2860
MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
MAPK-activated protein kinase- ...... ygenase-2 regulation in heart.
@ast
MAPK-activated protein kinase- ...... ygenase-2 regulation in heart.
@en
type
label
MAPK-activated protein kinase- ...... ygenase-2 regulation in heart.
@ast
MAPK-activated protein kinase- ...... ygenase-2 regulation in heart.
@en
prefLabel
MAPK-activated protein kinase- ...... ygenase-2 regulation in heart.
@ast
MAPK-activated protein kinase- ...... ygenase-2 regulation in heart.
@en
P2860
P1433
P1476
MAPK-activated protein kinase- ...... ygenase-2 regulation in heart.
@en
P2093
Harvey Herschman
Shuxun Ren
P2860
P304
P356
10.1161/CIRCRESAHA.109.213199
P577
2010-03-25T00:00:00Z